Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory of Diagnosis and Therapy of Lysosomal Disorders, |
RCV000677499 | SCV000803009 | pathogenic | Mucopolysaccharidosis type 6 | 2018-01-01 | criteria provided, single submitter | curation | Frameshift variant (PVS1); In vitro functional studies supportive of a damaging effect on the gene product (low to no ARSB activity in homozygotes; PS3); Absent from GnomAD (PM2) |
Institute of Medical Genetics and Applied Genomics, |
RCV001268662 | SCV001447753 | pathogenic | not provided | 2020-10-23 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000677499 | SCV001583435 | pathogenic | Mucopolysaccharidosis type 6 | 2023-07-13 | criteria provided, single submitter | clinical testing | This sequence change results in a frameshift in the ARSB gene (p.Thr526Metfs*48). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 8 amino acid(s) of the ARSB protein and extend the protein by 39 additional amino acid residues. This variant is not present in population databases (gnomAD no frequency). This frameshift has been observed in individual(s) with mucopolysaccharidosis type VI (PMID: 8116615, 24677745). ClinVar contains an entry for this variant (Variation ID: 559724). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this frameshift affects ARSB function (PMID: 8116615). For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV000677499 | SCV005055563 | pathogenic | Mucopolysaccharidosis type 6 | 2024-02-14 | criteria provided, single submitter | clinical testing |